Breaking News
Get 45% Off 0
🤯 +96%, +62%, +40%: These AI-picked stocks are soaring!
See the list

Should You Keep Your Portfolio Healthy With Biotech ETFs?

By Zacks Investment ResearchStock MarketsSep 12, 2017 03:08AM ET
www.investing.com/analysis/should-you-keep-your-portfolio-healthy-with-biotech-etfs-200212886
Should You Keep Your Portfolio Healthy With Biotech ETFs?
By Zacks Investment Research   |  Sep 12, 2017 03:08AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-1.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SPY
-1.75%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NOVOb
-0.84%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
VRTX
+0.73%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TEVA
-2.79%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GILD
+1.47%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

The biotech sector is going through the roof right now with SPDR S&P Biotech (MX:XBI) ETF XBI adding over 9% in a month (as of Sep 11, 2017). Plenty of factors are powering the sector. Among these, breakthrough U.S. Food and Drug Administration (FDA) approvals, success in the immune-oncology field, and mergers and acquisitions are at the forefront.

Biotech stock Vertex Pharmaceuticals (NASDAQ:VRTX) received a new FDA approval for cystic fibrosis drug, Kalydeco. In early September, FDA approved “Novartis AG' breakthrough gene transfer treatment, Kymriah (tisagenlecleucel) suspension for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse,” as per the source.

Investors should note that CAR-T is a fresh immunocellular therapy and many companies are eyeing it. In fact, Gilead Sciences (NASDAQ:GILD) announced the buyout of Kite Pharma (NYSE:K) for $11.9 billion in late August (read: Biotech ETFs Soar on Gilead-Kite Deal). Kite Pharma is expected to receive approval for its CAR-T therapy axicabtagene ciloleucel (axi-cel) shortly. With this acquisition, Gilead will step into the new arena of oncology treatment, known as CAR-T, which targets the body’s own immune system to fight tumors.

Two months ago, Clovis Oncology (NASDAQ:CLVS) shares also skyrocketed following the company’s positive cancer drug data. The company then said that clinical trial data on its ovarian cancer drug treatment indicated that it may substantially help more patients than expected (read: 4 Stocks & ETFs to Buy on Clovis' Positive Drug Data).

If this was not enough, Teva Pharmaceutical (NYSE:TEVA) TEVA shares surged over 19% on Sep 11 as it appointed a former Novo Nordisk (CO:NOVOb) (NVO) as CEO. The new recruitment followed Teva’s last full-time CEO’s seven-month term and resignation amid a bribery scandal.

Compelling Valuation

Biotech stocks were the most hurt among the S&P 500 members last year. This has probably made the space cheap and helped it to be back with a bang. Biotech ETF XBI added about 17.7% in the last three months (as of Sep 11, 2017) while SPDR S&P 500 ETF (NYSE:SPY) (AX:SPY) was up 2.9%. The fund XBI has a relative strength index of 66.95. This means that the fund is yet to enter the overbought territory.

Also, fears over price gouging are ebbing substantially in the Trump administration. In a nutshell, the space is riding on research and development and may log more returns ahead.

ETFs to Tap

Below we highlight a few biotech ETFs that can benefit investors with solid gains (see all Health Care ETFs here).

Direxion Daily S&P Biotech Bull 3X LABU

Ultrapro Nasdaq Biotechnology Proshares UBIO

ProShares Ultra Nasdaq Biotechnology BIB

iShare Nasdaq Biotech ETF IBB

Bioshares Biotech Clinical Trial (HM:BBC)

VanEck Vectors Biotech ETF (LON:BBH)

Bioshares Biotech Products (BS:BBP)

Loncar Cancer Immunotherapy ETF CNCR

ALPS Medical Breakthroughs ETF (SI:SBIO)

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>



SPDR-SP 500 TR (SPY): ETF Research Reports

ISHARES NDQ BIO (IBB): ETF Research Reports

PRO-ULT NDQ BIO (BIB): ETF Research Reports

LONCAR CANCER (CNCR): ETF Research Reports

DIRX-D SP BBULL (LABU): ETF Research Reports

PRO-ULT ND BI (UBIO): ETF Research Reports

BIOSH-BIO CLNCL (BBC): ETF Research Reports

BIOSH-BIO PRD (BBP): ETF Research Reports

SPDR-SP BIOTECH (XBI): ETF Research Reports

VANECK-BIOTECH (BBH): ETF Research Reports

ALPS-MED BRKTH (SBIO): ETF Research Reports

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report

Kellogg Company (K): Free Stock Analysis Report

Original post

Zacks Investment Research

Should You Keep Your Portfolio Healthy With Biotech ETFs?
 

Related Articles

Should You Keep Your Portfolio Healthy With Biotech ETFs?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email